• Friday, 10 September
  • Saturday, 11 September
  • Sunday, 12 September
General Session
State-of-the-Art Lecture
Symposium
Industry Symposium
Special Lecture
Workshop
TIME
08:00
09:30
ILCA Symposium 1
Management and outcomes of HCC in Asia
Chair: Sheng-Long Ye (P.R. China)
Metastatic recurrence of hepatocellular carcinoma: from –omics to clinical prediction
Lun-Xiu Qin (P.R. China)
Management and outcome of HCC in Japan: Analysis of 51,430 HCC cases registered in nationwide survey program of Liver Cancer Study Group of Japan
Masatoshi Kudo (Japan)
Surgical Management of HCC in Asia
Ronnie Poon (P.R. China)
09:30
10:00
Special Lecture 1: miRNA and HCC: biology and prognostic significance
Speaker: Xin Wang (USA)
10:00
10:30
Coffee and Networking Break
10:30
12:00
General Session 1: Pathways and gene expression profiles
Chairs: Yujin Hoshida, MD (USA) and Xin Wang, MD, PhD (USA)
12:00
13:30
Bayer Lunch Symposium
13:30
15:00
General Session 2: Biomarkers and novel targets
Chairs: Peter Schirmacher, MD (Germany) and Jorge Marrero, MD (USA)
15:00
16:30
ILCA Symposium 2
Novel targets and emerging therapies
Chair: Gregory Gores (USA)
Agents on the Horizon
Alan Venook (USA)
Novel oncogenes and tumor suppressors as therapeutic targets
Peter Galle (Germany)
Novel trial designs
Steven Alberts (USA)
16:30
17:00
Session Break
17:00
18:00
Sirtex Symposium
18:00
19:00
Welcome Reception
TIME
07:30
08:30
BMS Symposium
08:30
10:00
ILCA Symposium 3
Assessing response in HCC
Revisiting RECIST

Chair: JM Llovet (USA/Spain)
The concept: AASLD-JNCI guidelines
JM Llovet (USA/Spain)
Comparison of RECIST and proposed mRECIST
Riccardo Lencioni (Italy)
Response assessment with molecular therapies
Richard Finn (USA)
10:00
10:30
Coffee and Networking Break
10:30
12:00
ILCA Plenary General Session
Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Gregory Gores, MD (USA)
12:00
13:30
Luncheon workshop 1
Controversies in pathology: Mixed HCC and CC
Pierre Bedossa, (France) and Tania Roskams (Belgium)

Luncheon workshop 2
Molecular Signatures and prognosis

Yujin Hoshida (USA) and Ju-Seog Lee (USA)

Luncheon workshop 3

Surgical advancements in HCC
David Geller (USA) and Vincenzo Mazzaferro (Italy)

Luncheon workshop 4
Novel concepts in HCC staging
Jordi Bruix (Spain) and Masatoshi Kudo (Japan)

Luncheon workshop 5
Interventional radiology for HCC
Jean-Francois Geschwind (USA) and Riad Salem (USA)

13:30
14:30
State of the Art Lecture 1
Imaging of HCC and Early Diagnosis
Morris Sherman (Canada)
14:30
16:30
Poster Viewing
16:00
16:30
Coffee and Networking Break
16:30
18:00
General Session 3: Curative therapies
Chairs: Kim Olthoff, MD (USA) and Ronnie Poon, MD, PhD (China)
TIME
07:30
08:30
Novartis Symposium
08:30
09:00
ILCA General Assembly
09:00
10:30
General Session 4: Locoregional therapies
Chairs: Masatoshi Kudo, MD, PhD (Japan) and Riad Salem, MD (USA)
10:30
11:30
State of the Art Lecture 2
Relevant experimental models of HCC
Scott Lowe (USA) – tbc
11:30
12:00
>Coffee and Networking Break
12:00
13:30
General Session 5: Systemic therapies
Chairs: Andrew Zhu, MD, PhD (USA) and Ann-Li Chen, MD (USA)
13:30 >Closing Ceremony and Junior Investigator Awards